8-K filing — Jasper Therapeutics, Inc. (JSPR)
Filed: 2026-10-15 AccNo: 0001213900-26-109587 Size: 244 KB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Stocks · News reference
Jasper Therapeutics Announces Completion Of 18-Patient Enrollment In Phase 2 IgA Nephropathy Cohort Of Vensobafusp Alfa; Initial Data Expected By Year-End
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
William Blair Reinstates Outperform on Jasper Therapeutics
William Blair analyst Matt Phipps reinstates Jasper Therapeutics (NASDAQ:JSPR) with a Outperform.
Jasper Therapeutics Announces $0.324/Warrant Cash Tender Offer For All 12,345,707 Outstanding Warrants, Expiring November 6